Search

Displaying results 2791 - 2800 of 4859 in total
  1. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.

  2. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids

  3. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    It is a short acting local anesthetic that acts through inhibition of sodium channels.

  4. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

  5. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  6. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    It was also previously approved in the United States with orphan drug designation [L1469].

  7. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.

  8. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]

  9. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. … Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it

  10. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components. … In addition to the known catechin components, it also contains gallic acid, caffeine, and theobromine which together constitute about 2.5% of the drug substance.